Innovations in Oncology Diagnostics: Technological advances, growth opportunities and future market outlook - 2009/10/01 - Business Insights

Report title: Innovations in Oncology Diagnostics: Technological advances, growth opportunities and future market outlook

from Business Insights
141 page report published Oct 01, 2009

Price $3,835.00 available for immediate download

Report Overview

Table of Contents

Search Inside

About Business Insights

Despite public policy measures to prevent cancer, such as tobacco control and vaccination against HPV, cancer is sure to remain a significant public health problem throughout the 21st century. Indeed, the global demographic shift towards an ageing population and the spread of high tech modern medicine throughout the emerging economies of Asia and (maybe later) Africa, will expand the market for cancer diagnostics globally. Major developments are likely in both the IVD market and in imaging-based modalities, like computed tomography, with the emphasis being upon the personalized medicine approach, where demand will come from physicians, patients and payors â?? all of whom want more effective treatments and value for money. This report analyzes the latest innovations in oncology diagnostics and identifies the most exciting new technologies and trends, ranging from body imaging and cytology to molecular diagnostics and pharmacogenomics. The report also identifies the key challenges facing innovative diagnostics companies. Key Features of this report
-Analysis the latest innovations in diagnostics imaging in the oncology sector, covering Magnetic Resonance Imaging (MRI), x-ray, Computed Tomography (CT), ultrasound, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) and Flow Cytometry.
-Analyzes the latest innovations in molecular diagnostics and how they impact the diagnostics market. The report covers technology including fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), HPV testing, immunoassays & biomarkers, microarrays and comparative genomic hybridization (CGH).
-Analyzes the latest innovations in pharmacogenomics and covers the major applications for familial cancer, breast cancer, colon cancer and lung cancer. Also, the report provides an overview of the regulatory and intellectual property environment for genetic-based tests.
-Looks at the key commercial challenges for innovative diagnostics companies, including the impact of the recession, reimbursement, regulatory changes, pharmacoeconomics and the relationship between industry and academia.The report Includes in-depth case studies on the potential technologies available in core areas of un-met need such as ovarian cancer and colorectal cancer. Key benefits of this report
-Understand the latest innovations in the oncology diagnostics market in the core areas â?? diagnostic imaging, molecular diagnostics and pharmacogenetics. This includes market information and an analysis of the scientific literature so as to identify what is really innovative.
-Identify what the key areas of unmet need are in the oncology diagnostics market and understand which products have the greatest potential over the next decade.
-Understand what the greatest challenges are for oncology diagnostics and what the best strategies are for coping with these obstacles.
-Understand the competitive landscape and what companies are leading the way in terms of innovation, and what the latest partnerships regarding companion diagnostics.
-Business Insights has identified five key areas of innovation in the diagnostics markets, use this to help guide company strategy.Key findings from this reportMolecular diagnostics and biomarkers are the key drivers of the oncology diagnostics market.Despite the deep economic recession, R&D spending has held up for oncology diagnostics companies. However, M&A activity has been impacted with the value of deals conducted in 2009 far below the peak year of 2007.Partnerships between diagnostic firms and pharmaceutical firms represents the future of the industry and the number of companion deals has been increasing in the past few years. Virtual colonoscopy - using CT scans to build a picture of the colon - is becoming an increasingly accepted alternative to invasive colonoscopy for colorectal screening in high risk groups and the general population. This presents a sizeable mark

Source:

Business Insights

Document ID:

rbdg0007

Industry:

Health Care

Industry:

Pharmaceutical

Free Sample:

Click Here to Download

Format:

PDF

Title	Starting Page	Number of Pages
Sections
Table of Contents Innovations in oncology diagnostics Executive summary 10 Setting the scene 10 Innovations in diagnostic imaging 11 Innovations in molecular diagnostics 12 Innovations in pharmacogenomics 13 Challenges in the oncology diagnostics sector 14	0	1
Table of Contents	0	1
Innovations in oncology diagnostics	0	1
Executive summary 10	0	1
Setting the scene 10	0	1
Innovations in diagnostic imaging 11	0	1
Innovations in molecular diagnostics 12	0	1
Innovations in pharmacogenomics 13	0	1
Challenges in the oncology diagnostics sector 14	0	1
Competitive landscape 15	0	1
Chapter 1 Setting the scene 18	0	1
Summary 18	0	1
Introduction 19	0	1
Cancer facts, current and projected 19	0	1
History of oncology diagnostics 23	0	1
Elements of a cancer diagnosis 26	0	1
Pathology 27	0	1
Oncology diagnostics market 28	0	1
Chapter 2 Innovations in diagnostic imaging 34	0	1
Summary 34	0	1
Introduction 35	0	1
Body imaging 35	0	1
Overview 35	0	1
X-ray 38	0	1
Breast cancer 38	0	1
Computed tomography 40	0	1
Lung cancer 40	0	1
Colon cancer 40	0	1
Others 42	0	1
Ultrasound 44	0	1
Magnetic resonance imaging 44	0	1
Nuclear medicine â€“ PET & SPECT 45	0	1
Case study 47	0	1
HYPERImage 47	0	1
Cytology 47	0	1
Overview 47	0	1
Flow cytometry 48	0	1
Case study 49	0	1
CellSearch 49	0	1
Cervical screening 50	0	1
Cytogenetics 52	0	1
Chapter 3 Innovations in molecular diagnostics 56	0	1
Summary 56	0	1
Introduction 57	0	1
DNA, genes and chromosomes 59	0	1
Fluorescence in situ hybridization (FISH) 59	0	1
PCR and variants 60	0	1
Case study 61	0	1
HPV testing 61	0	1
Immunoassays and biomarkers 62	0	1
Case study 66	0	1
Ovarian cancer 66	0	1
PSA testing 68	0	1
Other areas of research 70	0	1
Epigenomics 71	0	1
Microarrays 72	0	1
Comparative genomic hybridization (CGH) 73	0	1
Case study 74	0	1
Almac 74	0	1
DiaGenic 74	0	1
Overview of clinical applications of molecular diagnostics 74	0	1
BCR-ABL 74	0	1
LOH 75	0	1
MSI 75	0	1
Chapter 4 Innovations in pharmacogenomics 78	0	1
Summary 78	0	1
Introduction 79	0	1
Familial cancer 79	0	1
Breast cancer 80	0	1
Colon cancer 81	0	1
Melanoma 81	0	1
Case study 82	0	1
IP challenge 82	0	1
Response to therapy 83	0	1
Cytochrome P450 variants 86	0	1
HER2 overexpression 86	0	1
The FDA, EMEA and PGx labeling 88	0	1
Case study 89	0	1
TheraScreen: KRAS 89	0	1
BioTheranostics: Breast cancer 89	0	1
Clarient: Breast cancer 90	0	1
Marker validation for erlotinib in lung cancer 90	0	1
Companion diagnostics 91	0	1
Chapter 5 Challenges in the oncology diagnostics sector 94	0	1
Summary 94	0	1
Introduction 95	0	1
Reimbursement funding 97	0	1
Educated patients = educated decisions 98	0	1
Regulation 99	0	1
Pharmacoeconomics 101	0	1
Emerging markets 104	0	1
Partnerships between drug companies & academia 105	0	1
Research & development 106	0	1
Mergers & acquisitions 109	0	1
Chapter 6 Competitive landscape 112	0	1
Summary 112	0	1
Introduction 113	0	1
Abbot Diagnostics 113	0	1
Affymetrix 114	0	1
Beckman Coulter 116	0	1
Becton Dickinson 117	0	1
Bio-Rad Laboratories 119	0	1
Gen-Probe 120	0	1
Johnson & Johnson (J&J) 121	0	1
Ortho Clinical Diagnostics 121	0	1
Luminex 121	0	1
Tm Bioscience 122	0	1
Nanogen 122	0	1
Roche Diagnostics 123	0	1
Siemens Healthcare Diagnostics 126	0	1
Sysmex 126	0	1
Future perspectives in the oncology diagnostics market 127	0	1
Science 127	0	1
Infrastructure 128	0	1
Adoption of innovation 130	0	1
Companion diagnostics 131	0	1
Chapter 7 Appendix 135	0	1
Glossary 135	0	1
Index 138	0	1
List of Figures	0	1
Figure 1.1: Leading sites of new cancer US, 2009 22	0	1
Figure 1.2: Leading sites of new cancer in developing countries, 2007 23	0	1
Figure 1.3: Information required by oncologist pre/post diagnosis 27	0	1
Figure 1.4: Oncology diagnostics forecasts ($bn), 2007-14 30	0	1
Figure 2.5: Example of the use of 3D tomosynthesis imaging 39	0	1
Figure 2.6: Number of CT scans in the US, 1995-2008 43	0	1
Figure 2.7: Women having mammograms (%) in the US, 2004* 45	0	1
Figure 2.8: Global flow cytometry market forecast ($bn), 2008-14 48	0	1
Figure 3.9: IV diagnostics market forecast ($bn), 2007-2014) 58	0	1
Figure 3.10: Use of biomarkers 63 Figure 3.11: Obstacles to biomarker development 64 Figure 3.12: US 5-year survival (%) for ovarian cancer at time of diagnosis 67 Figure 4.13: Myriad: Molecular diagnostics sales ($m), 2005-09 83 Figure 4.14: Number of bio	0	1

Enter the keyword(s) which you would like to search for within this document and click "Search"

Business Insights provides a single, off-the-shelf, objective source of data, analysis and market insight. Business Insights work in association with leading industry experts to produce a range of reports across a wide range of industry sectors.

Price: $3,835.00

Free Sample

Questions about
this research?

Send page to a friend

Return to
Alacra Company Snapshot

Can't Decide?

Purchasing premium research sight unseen can be intimidating. At Alacra we want you to know what you are getting. Visit our FAQ or ask our Customer Service Team any questions about the report you are considering purchasing.